Analysed UNICYCIVE THERAPEUTICS INC (UNCY:NASDAQ) News Sources
Hyperphosphatemia Market Set for Robust Growth During the Forecast Period (2026-2036), Driven by Novel Therapeutics and Rising CKD Burden | DelveInsight
05-08-2026
yahoo.com
Unicycive Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference
09-04-2026
yahoo.com
Unicycive Therapeutics Announces Full Year 2025 Financial Results and Provides Business Update
30-03-2026
yahoo.com
Unicycive Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Update
12-05-2026
yahoo.com
Unicycive Therapeutics (UNCY) Pivots From Profit To Loss And Expands Equity Pool Is The Story Changing?
14-05-2026
yahoo.com
Unicycive Therapeutics Receives Complete Response Letter from FDA Regarding Resubmitted Oxylanthanum Carbonate (OLC) New Drug Application (NDA)
30-06-2026
yahoo.com
Unicycive shares plunge after FDA issues Complete Response Letter for kidney disease drug (UNCY)
30-06-2026
advfn.com
Unicycive Therapeutics (UNCY) Is Down 33.1% After FDA CRL Cites Third-Party Manufacturing Deficiencies
01-07-2026
yahoo.com
What is the current price of UNICYCIVE THERAPEUTICS INC (UNCY:NASDAQ)?
The current price of UNICYCIVE THERAPEUTICS INC (UNCY:NASDAQ) is $5.29.
UNICYCIVE THERAPEUTICS INC (UNCY:NASDAQ) absolute price change since previous trading day?
The absolute price change of UNICYCIVE THERAPEUTICS INC (UNCY:NASDAQ) since the previous trading day is $-0.02.
UNICYCIVE THERAPEUTICS INC (UNCY:NASDAQ) percentage price change since previous trading day?
The percentage price change of UNICYCIVE THERAPEUTICS INC (UNCY:NASDAQ) since the previous trading day is -0.3766%.
What is the most recent average sentiment score for UNICYCIVE THERAPEUTICS INC (UNCY:NASDAQ)?
The most recent average sentiment score for UNICYCIVE THERAPEUTICS INC (UNCY:NASDAQ) is 70 out of 100.
What is the most recent average sentiment for UNICYCIVE THERAPEUTICS INC (UNCY:NASDAQ)?
The most recent sentiment for UNICYCIVE THERAPEUTICS INC (UNCY:NASDAQ) is .
SEC-8K** Filing Available For UNICYCIVE THERAPEUTICS INC (UNCY:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.